Objective: To analyze the expression of Livin protein in human bladder cancer tissues and its correlation with bladder cancer. Methods: Literatures related to this study were searched in Chinese databases such as China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, Chinese Science and Technology Journal Database, SinoMed, and English databases such as Pubmed, Web of Science, ScienceDirect and The Cochrane Library. Revman 5.4 and Stata 16.0 software were used for statistical analysis of the extracted data, such as the number of cases, patient gender, tumor stage and grade. Results: A total of 22 clinical trials were included, with a total number of 1 128 cases. The results showed that the positive rate of Livin expression in bladder cancer tissues was higher than that in normal bladder tissues (OR=36.02, 95%CI: 23.95-54.14, P＜0.05). Livin expression was positively correlated with tumor recurrence and tumor T stage (OR=5.78, 95%CI:3.41-9.80, P＜0.05; OR=1.73, 95%CI:1.30-2.31, P＜0.05). Conclusion: Compared with the control group, the positive expression rate of Livin protein in bladder cancer tissues is increased, and it is related to the malignant biological behavior and poor prognosis of the tumor, indicating that it may play a role in the occurrence and development of bladder cancer, and may be used as a predictor of early recurrence of bladder cancer.
[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2] Han BF, Zheng RS, Zeng HM, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
[3] Lenis AT, Lec PM, Chamie K, et al. Bladder cancer[J]. JAMA, 2020, 324(19): 1980.
[4] van Kessel KEM, Zuiverloon TCM, Alberts AR, et al. Targeted therapies in bladder cancer: an overview of in vivo research[J]. Nat Rev Urol, 2015, 12(12): 681-694.
[5] Wolf P. Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer[J]. Front Oncol, 2023, 13: 1124600.
[6] Yan B. Research progress on livin protein: an inhibitor of apoptosis[J]. Mol Cell Biochem, 2011, 357(1/2): 39-45.
[7] Ashhab Y, Alian A, Polliack A, et al. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern[J]. FEBS Lett, 2001, 495(1/2): 56-60.
[8] 易正金, 杨林, 吴小候, 等. 膀胱癌患者尿液脱落细胞Livin检测的临床意义[J]. 现代泌尿外科杂志, 2007, 12(3): 179-181.
[9] Li XW, Fu CH, Li GF, et al. RNA-seq reveals novel mechanistic targets of Livin in bladder cancer[J]. BMC Urol, 2023, 23(1): 26.
[10] 董丰铭, 王文瑞, 刘屹立. 丝氨酸/精氨酸富集剪接因子1和Livin在膀胱移行细胞癌中的表达及临床意义[J]. 中华实用诊断与治疗杂志, 2018, 32(9): 862-864.
[11] 丁德鑫, 陈辉, 王志, 等. 腺性膀胱炎及膀胱癌中livin和caspase-9的表达[J]. 现代生物医学进展, 2016, 16(6): 1076-1078, 1179.
[12] 晋学飞, 吴冰, 谭九峰, 等. 生存素、Livin和zeste同源物-2在膀胱癌组织中的表达[J]. 中华实验外科杂志, 2015, 32(6): 1230-1232.
[13] 吴德柱, 林雨冬, 李清林, 等. 膀胱尿路上皮癌中Livin蛋白的表达及临床意义[J]. 华南国防医学杂志, 2014, 28(5): 445-448.
[14] 张勇, 陈忠, 杨为民, 等. Livin和HIF-1α在膀胱尿路上皮癌中的表达及意义[J]. 临床泌尿外科杂志, 2013, 28(4): 268-270.
[15] 陈辉, 陈荣生, 李剑, 等. Livin蛋白在膀胱移行细胞癌中的表达及其与生物学行为的关系[J]. 中国药物与临床, 2013, 13(3): 314-315.
[16] 张二军. Livin蛋白和Smac蛋白在膀胱尿路上皮癌中的表达及临床意义[D]. 蚌埠: 蚌埠医学院, 2012.
[17] 李清林, 蒋雷鸣, 伍运筹, 等. Livin和Smac在膀胱移行细胞癌中的表达及相关性研究[J]. 天津医药, 2012, 40(4): 334-336, 419.
[18] 郑佐柱, 郑雯雯, 贺磊磊, 等. 凋亡抑制因子Livin在膀胱移行细胞癌组织中的表达及意义[J]. 中国老年学杂志, 2012, 32(15): 3170-3171.
[19] 蒋旭敏, 赵益华, 张华, 等. 膀胱移行细胞癌组织中Livin的表达及临床意义[J]. 中国药物与临床, 2011, 11(11): 1278-1279.
[20] 谢文君, 李晓虹, 付天红. Livin蛋白在膀胱移行细胞癌组织芯片中的表达及临床意义[J]. 中国现代医生, 2011, 49(31): 88-89.
[21] 高伟兴, 张新, 张立国, 等. 膀胱尿路上皮癌组织中Livin蛋白的表达与预后的关系[J]. 西部医学, 2011, 23(2): 236-238.
[22] 韩兴涛. Livin、Caspase-3和MVD在膀胱癌中的表达及意义[D]. 郑州: 郑州大学, 2009.
[23] 岳峰. 凋亡抑制蛋白Livin在膀胱移行细胞癌中的表达及其临床意义[D]. 大连: 大连医科大学, 2008.
[24] 李淑峰, 董永良, 董艳君, 等. 膀胱移行细胞癌组织中Livin和VEGF的表达及意义[J]. 山东医药, 2008, 48(33): 77-78.
[25] 祝兴旺, 宋彦, 张明明, 等. 凋亡相关蛋白Livin及Caspase-3在膀胱移行细胞癌中的表达及临床意义[J]. 医学临床研究, 2008, (11): 1955-1957, 1960.
[26] 董永良. Livin和VEGF在膀胱移行细胞癌中的表达及其临床意义的研究[D]. 石家庄: 河北医科大学, 2008.
[27] 陈小刚, 任昌慧, 张青汉, 等. 膀胱癌中Livin的表达及其与突变型P53的关系[J]. 现代泌尿外科杂志, 2008, 13(5): 362-364.
[28] 王艳波. 凋亡抑制基因Livin在膀胱移行细胞癌中的表达及临床意义[D]. 武汉: 华中科技大学, 2008.
[29] 韩锋. Livin、Caspase-3、Ki-67在膀胱移行细胞癌中的表达及相关性研究[D]. 蚌埠: 蚌埠医学院, 2008.
[30] 朱朝辉, 王艳波, 曾甫清, 等. 凋亡抑制因子Livin在膀胱移形细胞癌中的表达[J]. 中华实验外科杂志, 2007, 24(11): 1369-1371, 1447.
[31] 何远桥, 曾甫清, 汪良. Livin在膀胱移行细胞癌中的表达及其与ki-67的关系[J]. 临床外科杂志, 2006, 14(6): 369-371, 403.
[32] Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020[J]. CA Cancer J Clin, 2020, 70(5): 404-423.
[33] Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member[J]. J Biol Chem, 2001, 276(5): 3238-3246.
[34] 杨立军, 郑文武, 周安传, 等. 膀胱尿路上皮癌组织Livin和BCL-2的表达及其相关性研究[J]. 河北医药, 2017, 39(8): 1228-1230, 1233.
[35] Vucic D, Stennicke HR, Pisabarro MT, et al. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas[J]. Curr Biol, 2000, 10(21): 1359-1366.
[36] El-Mesallamy HO, Hegab HM, Kamal AM. Expression of inhibitor of apoptosis protein (IAP) livin/BIRC7 in acute leukemia in adults: correlation with prognostic factors and outcome[J]. Leuk Res, 2011, 35(12): 1616-1622.
[37] Tanabe H, Yagihashi A, Tsuji N, et al. Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer[J]. Lung Cancer, 2004, 46(3): 299-304.
[38] Gazzaniga P, Gradilone A, Giuliani L, et al. Expression and prognostic significance of LIVIN SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer[J]. Ann Oncol, 2003, 14(1): 85-90.
[39] Wang JW, Zhang XD, Wei P, et al. Livin, Survivin and Caspase 3 as early recurrence markers in non-muscle-invasive bladder cancer[J]. World J Urol, 2014, 32(6): 1477-1484.
